Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Vitamin A (retinyl acetate) is scientifically validated for use in the management of measles, particularly in children. Numerous clinical trials and meta-analyses have demonstrated that vitamin A supplementation in children with measles significantly reduces morbidity and mortality, especially in those who are hospitalized or have evidence of vitamin A deficiency. The World Health Organization (WHO) and UNICEF recommend high-dose vitamin A supplementation for all children diagnosed with measles in areas where vitamin A deficiency may be present, or where case fatality rates from measles are high. This recommendation is based on robust evidence showing that vitamin A supports immune function, maintains the integrity of mucosal barriers, and helps reduce the severity and complications of measles, including pneumonia and ocular complications like blindness.

A landmark meta-analysis published in the British Medical Journal (1993) and a Cochrane review (2005, updated 2011) found that vitamin A supplementation in children with measles reduces the risk of death by about 50%. The greatest benefit is seen in children under two years of age, those hospitalized with severe disease, and those with evidence of vitamin A deficiency. Because of this strong scientific backing, vitamin A is included in measles treatment protocols in many countries.

In summary, the use of vitamin A for measles is grounded in high-quality scientific evidence, with global health authorities endorsing its use to improve outcomes and reduce mortality in affected children.

More about Vitamin A (retinyl acetate)
More about Measles

Other ingredients used for Measles

Other health conditions supported by Vitamin A (retinyl acetate)

Products containing Vitamin A (retinyl acetate)